Literature DB >> 19081806

Estimating Time to Event From Longitudinal Categorical Data: An Analysis of Multiple Sclerosis Progression.

Micha Mandel1, Susan A Gauthier, Charles R G Guttmann, Howard L Weiner, Rebecca A Betensky.   

Abstract

The expanded disability status scale (EDSS) is an ordinal score that measures progression in multiple sclerosis (MS). Progression is defined as reaching EDSS of a certain level (absolute progression) or increasing of one point of EDSS (relative progression). Survival methods for time to progression are not adequate for such data since they do not exploit the EDSS level at the end of follow-up. Instead, we suggest a Markov transitional model applicable for repeated categorical or ordinal data. This approach enables derivation of covariate-specific survival curves, obtained after estimation of the regression coefficients and manipulations of the resulting transition matrix. Large sample theory and resampling methods are employed to derive pointwise confidence intervals, which perform well in simulation. Methods for generating survival curves for time to EDSS of a certain level, time to increase of EDSS of at least one point, and time to two consecutive visits with EDSS greater than three are described explicitly. The regression models described are easily implemented using standard software packages. Survival curves are obtained from the regression results using packages that support simple matrix calculation. We present and demonstrate our method on data collected at the Partners MS center in Boston, MA. We apply our approach to progression defined by time to two consecutive visits with EDSS greater than three, and calculate crude (without covariates) and covariate-specific curves.

Entities:  

Year:  2007        PMID: 19081806      PMCID: PMC2600443          DOI: 10.1198/016214507000000059

Source DB:  PubMed          Journal:  J Am Stat Assoc        ISSN: 0162-1459            Impact factor:   5.033


  15 in total

Review 1.  Modelling ordered categorical data: recent advances and future challenges.

Authors:  A Agresti
Journal:  Stat Med       Date:  1999 Sep 15-30       Impact factor: 2.373

2.  Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process.

Authors:  Christian Confavreux; Sandra Vukusic; Patrice Adeleine
Journal:  Brain       Date:  2003-04       Impact factor: 13.501

3.  Marginalized transition models and likelihood inference for longitudinal categorical data.

Authors:  Patrick J Heagerty
Journal:  Biometrics       Date:  2002-06       Impact factor: 2.571

4.  Not every patient with multiple sclerosis should be treated at time of diagnosis.

Authors:  Sean J Pittock; Brian G Weinshenker; John H Noseworthy; Claudia F Lucchinetti; Mark Keegan; Dean M Wingerchuk; Jonathan Carter; Elizabeth Shuster; Moses Rodriguez
Journal:  Arch Neurol       Date:  2006-04

5.  Modeling animals' behavioral response by Markov chain models for capture-recapture experiments.

Authors:  Hsin-Chou Yang; Anne Chao
Journal:  Biometrics       Date:  2005-12       Impact factor: 2.571

6.  Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group.

Authors:  R B D'Agostino
Journal:  Stat Med       Date:  1998-10-15       Impact factor: 2.373

7.  The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course.

Authors:  B G Weinshenker; B Bass; G P Rice; J Noseworthy; W Carriere; J Baskerville; G C Ebers
Journal:  Brain       Date:  1989-12       Impact factor: 13.501

8.  A Markov model for sequences of ordinal data from a relapsing-remitting disease.

Authors:  P S Albert
Journal:  Biometrics       Date:  1994-03       Impact factor: 2.571

9.  Relapses and progression of disability in multiple sclerosis.

Authors:  C Confavreux; S Vukusic; T Moreau; P Adeleine
Journal:  N Engl J Med       Date:  2000-11-16       Impact factor: 91.245

10.  Multicentre, randomised, double blind, placebo controlled, phase III study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosis.

Authors:  O Andersen; I Elovaara; M Färkkilä; H J Hansen; S I Mellgren; K-M Myhr; M Sandberg-Wollheim; P Soelberg Sørensen
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-05       Impact factor: 10.154

View more
  6 in total

1.  Simultaneous Confidence Intervals Based on the Percentile Bootstrap Approach.

Authors:  Micha Mandel; Rebecca A Betensky
Journal:  Comput Stat Data Anal       Date:  2008-01-10       Impact factor: 1.681

2.  Psychiatric comorbidity is associated with disability progression in multiple sclerosis.

Authors:  Kyla A McKay; Helen Tremlett; John D Fisk; Tingting Zhang; Scott B Patten; Lorne Kastrukoff; Trudy Campbell; Ruth Ann Marrie
Journal:  Neurology       Date:  2018-03-09       Impact factor: 9.910

3.  Estimating time to disease progression comparing transition models and survival methods--an analysis of multiple sclerosis data.

Authors:  Micha Mandel; Francois Mercier; Benjamin Eckert; Peter Chin; Rebecca A Betensky
Journal:  Biometrics       Date:  2013-02-14       Impact factor: 2.571

4.  Estimating time-to-event from longitudinal ordinal data using random-effects Markov models: application to multiple sclerosis progression.

Authors:  Micha Mandel; Rebecca A Betensky
Journal:  Biostatistics       Date:  2008-04-18       Impact factor: 5.899

5.  Semiparametric Mixed Effect Model with Application to the Longitudinal Knee Osteoarthritis (OAK) Data.

Authors:  Huiyong Zheng; Maryfran Sowers; Carrie Karvonen-Gutierrez; Jon A Jacobson; John F Randolph; Siobàn D Harlow
Journal:  J Syst Cybern Inf       Date:  2012

6.  Developing a clinical-environmental-genotypic prognostic index for relapsing-onset multiple sclerosis and clinically isolated syndrome.

Authors:  Valery Fuh-Ngwa; Yuan Zhou; Jac C Charlesworth; Anne-Louise Ponsonby; Steve Simpson-Yap; Jeannette Lechner-Scott; Bruce V Taylor
Journal:  Brain Commun       Date:  2021-12-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.